Adage Capital Partners’s ProQR Therapeutics PRQR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $16.8M | Buy |
9,015,897
+2,762,430
| +44% | +$4.55M | 0.02% | 569 |
|
|
2026
Q1 | $10.1M | Hold |
6,253,467
| – | – | 0.02% | 683 |
|
|
2025
Q4 | $12.6M | Hold |
6,253,467
| – | – | 0.02% | 617 |
|
|
2025
Q3 | $13.3M | Sell |
6,253,467
-348,471
| -5% | -$761K | 0.02% | 577 |
|
|
2025
Q2 | $13.5M | Sell |
6,601,938
-1,500,160
| -19% | -$2.44M | 0.02% | 550 |
|
|
2025
Q1 | $10.8M | Sell |
8,102,098
-1,500,182
| -16% | -$3.19M | 0.02% | 571 |
|
|
2024
Q4 | $25.4M | Buy |
9,602,280
+5,976,813
| +165% | +$19M | 0.04% | 376 |
|
|
2024
Q3 | $6.6M | Hold |
3,625,467
| – | – | 0.01% | 684 |
|
|
2024
Q2 | $6.02M | Hold |
3,625,467
| – | – | 0.01% | 689 |
|
|
2024
Q1 | $8.3M | Hold |
3,625,467
| – | – | 0.02% | 633 |
|
|
2023
Q4 | $7.18M | Hold |
3,625,467
| – | – | 0.01% | 646 |
|
|
2023
Q3 | $4.71M | Hold |
3,625,467
| – | – | 0.01% | 671 |
|
|
2023
Q2 | $5.87M | Hold |
3,625,467
| – | – | 0.01% | 652 |
|
|
2023
Q1 | $7.72M | Hold |
3,625,467
| – | – | 0.02% | 660 |
|
|
2022
Q4 | $13.4M | Buy |
3,625,467
+325,467
| +10% | +$426K | 0.03% | 557 |
|
|
2022
Q3 | $2.46M | Hold |
3,300,000
| – | – | 0.01% | 842 |
|
|
2022
Q2 | $2.57M | Hold |
3,300,000
| – | – | 0.01% | 866 |
|
|
2022
Q1 | $2.99M | Sell |
3,300,000
-1,415,152
| -30% | -$4.74M | 0.01% | 874 |
|
|
2021
Q4 | $37.8M | Hold |
4,715,152
| – | – | 0.07% | 292 |
|
|
2021
Q3 | $39.5M | Buy |
4,715,152
+20,687
| +0.4% | +$135K | 0.08% | 257 |
|
|
2021
Q2 | $31.6M | Hold |
4,694,465
| – | – | 0.06% | 326 |
|
|
2021
Q1 | $31M | Buy |
4,694,465
+144,403
| +3% | +$738K | 0.06% | 320 |
|
|
2020
Q4 | $19.1M | Hold |
4,550,062
| – | – | 0.04% | 424 |
|
|
2020
Q3 | $21.8M | Hold |
4,550,062
| – | – | 0.05% | 352 |
|
|
2020
Q2 | $27.7M | Hold |
4,550,062
| – | – | 0.07% | 305 |
|
|
2020
Q1 | $25M | Sell |
4,550,062
-21,257
| -0.5% | -$163K | 0.07% | 273 |
|
|
2019
Q4 | $45.3M | Buy |
4,571,319
+835,812
| +22% | +$6.51M | 0.11% | 225 |
|
|
2019
Q3 | $21.5M | Hold |
3,735,507
| – | – | 0.05% | 349 |
|
|
2019
Q2 | $34M | Hold |
3,735,507
| – | – | 0.08% | 266 |
|
|
2019
Q1 | $51.8M | Hold |
3,735,507
| – | – | 0.13% | 194 |
|
|
2018
Q4 | $58.9M | Buy |
3,735,507
+273,566
| +8% | +$5.02M | 0.16% | 164 |
|
|
2018
Q3 | $67M | Buy |
3,461,941
+1,299,414
| +60% | +$13.8M | 0.15% | 172 |
|
|
2018
Q2 | $15.8M | Buy |
2,162,527
+662,527
| +44% | +$3.34M | 0.04% | 464 |
|
|
2018
Q1 | $4.61M | Buy |
1,500,000
+500,000
| +50% | +$1.61M | 0.01% | 644 |
|
|
2017
Q4 | $3.22M | Buy |
+1,000,000
| New | +$3.59M | 0.01% | 649 |
|
Other funds holding PRQR
KCM
Adage Capital Partners's PRQR Position: Q2 2026 in Review
Adage Capital Partners increased its ProQR Therapeutics (PRQR) stake by 44% in Q2 2026, buying an estimated $4.55M and bringing the position to 9,015,897 shares worth $16.8M. The position accounts for 0.02% of the portfolio, ranked #569.
Adage Capital Partners first reported a position in PRQR in Q4 2017 and has held it in 35 quarters since. The position peaked at $67M in Q3 2018. 71 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.
- Adage Capital Partners held 9,015,897 shares of ProQR Therapeutics worth $16.8M as of Q2 2026.
- Adage Capital Partners bought 2,762,430 ProQR Therapeutics shares in Q2 2026, an estimated $4.55M.
- ProQR Therapeutics made up 0.02% of Adage Capital Partners's portfolio in Q2 2026, its #569 holding.
- Adage Capital Partners first reported a position in ProQR Therapeutics in Q4 2017 and has held it in 35 quarters since.
- Adage Capital Partners's ProQR Therapeutics position peaked at $67M in Q3 2018.
- 71 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.
Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.